Clinical trials: Functional Disorder of Gastrointestinal Tract
Irritable Bowel Syndrome
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
- Trial name
- NCT02544152
- Testing
- Lubiprostone
- Where
- 16 sites in United States
- Volunteers
- 71 people
- Sponsor
- Sucampo Pharma Americas, LLC
Irritable Bowel Syndrome
Comparison of Rimegepant and Placebo for Pain in IBS
The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.
- Trial name
- NCT06221111
- Testing
- Rimegepant 75 MG [Nurtec]
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
IBS - Irritable Bowel Syndrome
Zemedy Application for Irritable Bowel Syndrome
The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.
- Trial name
- NCT04723056
- Testing
- Use of Zemedy Application
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Major Depression, Irritable Bowel Syndrome
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
This study will evaluate the efficacy of duloxetine in reducing depressive symptoms, abdominal pain, and other symptoms of Irritable Bowel Syndrome (IRS) in a population of outpatients with Major Depressive Disorder MDD and…
- Trial name
- IBS-MDD (NCT01754493)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Cystic Fibrosis
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03447249
- Testing
- VX-659/TEZ/IVA, IVA
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 385 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Autism Spectrum Disorder
Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder
The purpose of this study is to assess the effects of 3 months supplementation with the multi strain probiotic Vivomixx on the overall function, aberrant behaviours and frequency of gastrointestinal symptoms in children with…
- Trial name
- VIVO-ASD (NCT03369431)
- Testing
- Vivomixx
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- University College, London
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Many people with Cystic Fibrosis (CF) are troubled by symptoms from their stomach and bowels: their gastrointestinal (GI) tract.
- Trial name
- GIFT-CF1 (NCT03566550)
- Testing
- MRI scans
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Irritable Bowel Syndrome
SH-DS01 on Fecal Metagenomic Stability
This is a randomized, double blind, Phase 1 study. There will be a 12-week comparison of the safety of DS-01 versus placebo with a secondary outcome measure of the efficacy in a cohort of 100 men or women with IBS with…
- Trial name
- NCT04598295
- Testing
- DS-01
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Beth Israel Deaconess Medical Center
Sarcopenia
Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults
The investigators recently published significant associations between circulating gut bacteria-related metabolites with lean and skeletal muscle mass and with measures of physical function in older adults, evidence that suggests…
- Trial name
- NCT02811445
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Tufts University
Irritable Bowel Syndrome
Citalopram in Irritable Bowel Syndrome
Hypotheses: 1. Primary null hypothesis: The rate of clinical response, assessed as patient-reported global symptom rating and "adequate relief of IBS symptoms," does not differ between non-depressed IBS patients treated with the…
- Trial name
- NCT00477165
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Stanford University
Visceral Hypersensitivity, Irritable Bowel Syndrome
Rifaximin on Visceral Hypersensitivity
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders, with a global prevalence of 11% according to a recent meta-analysis.
- Trial name
- NCT03462966
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Obstructed Defecation Syndrome, Rectocele
Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM
The stapled transanal rectal resection (STARR procedure) is an effective treatment for obstructed defecation syndrome (ODS) caused by intussusception and rectocele.
- Conditions
- Obstructed Defecation Syndrome, Rectocele, Intussusception, SNS
- Trial name
- STARR (NCT00673400)
- Testing
- Stapled transanal rectum resection
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- Cantonal Hospital of St. Gallen
Constipation-Predominant Irritable Bowel Syndrome
Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome
The purpose of this study is to determine whether Mosapride, an agent which acts on serotonin receptors in the gastrointestinal tract, is effective in the treatment of constipation-predominant irritable bowel syndrome (C-IBS).
- Trial name
- NCT00742872
- Testing
- Mosapride Citrate
- Where
- Lebanon
- Volunteers
- 41 people
- Sponsor
- American University of Beirut Medical Center
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dysbiosis, Endotoxemia
Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults.
- Conditions
- Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
- Trial name
- NCT03973996
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Cystic Fibrosis
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
The purpose of this study evaluates the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who were heterozygous for F508del and a minimal function mutation (F/MF participants).
- Trial name
- NCT05033080
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 139 sites in United States, Australia and 10 more
- Volunteers
- 435 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology